Details

NameSymbolSector
GLAXOSMITHKLINE PHARMACEUTICALS LTD.GLAXOPharmaceuticals
Open
2135.1
High
2169.8
Low
2111
Close
2122.5
Volume
162107
Exchange
nse
Time
15-Jun-2026

Outlook

Score:

1.5

Rating:

RISKY

Candlestick Pattern

CandlepatternofGlaxosmithklinePharmaceuticalsis
Short Line
EstimatedStoplossofGlaxosmithklinePharmaceuticalsis
2169.8
GlaxosmithklinePharmaceuticalshasa
Bearishℹ
pattern.
Formationof
Short Line
candlepatternindicatesthetrenddirectionofGlaxosmithklinePharmaceuticalsis
Unpredictableℹ
.

Trend

GlaxosmithklinePharmaceuticalsisin
Downtrendℹ
.
PriceofGlaxosmithklinePharmaceuticalsis
Downℹ
by

8.25

%.
Target
Buy@

2088.1

Sell@

2397.8

Current@

2122.5

Volume

ThetradesofGlaxosmithklinePharmaceuticalshavebeenin
Immenseℹ
volume.
ThevolumetradesforGlaxosmithklinePharmaceuticalsare
Bearishℹ
with
Strong Sellersℹ
ThetradevolumeofGlaxosmithklinePharmaceuticalsis

Up

by

94.31

%

Valuation

ThecurrentmarketpriceofGlaxosmithklinePharmaceuticalsis
Fairℹ

Financials

Balance
Withtotalliablitiesandshareholderequityworth4108crandtotalassetsworth4108cr,thebalancesheetofGlaxosmithklinePharmaceuticalsis:
Balancedℹ
.
Cashflow
GlaxosmithklinePharmaceuticalshas
Excellentℹ
cashflowbecausethereis

Surplus

of

₹ 474cr

.Itis
Upℹ
by

1534.48

%.
61.29% i.e. ₹ 1289cr earned in operatingℹ
2.14% i.e. ₹ 45cr spent in investingℹ
36.57% i.e. ₹ 769cr spent in financingℹ
0% in otherℹ
GlaxosmithklinePharmaceuticalshas
Maintainedℹ
cashflowbecausethereis

Surplus

of

₹ 29cr

.Itis
Upℹ
by

111.55

%.
50.56% i.e. ₹ 582cr earned in operatingℹ
0.7% i.e. ₹ 8cr earned in investingℹ
48.74% i.e. ₹ 561cr spent in financingℹ
0% in otherℹ
Income
TheincomeofGlaxosmithklinePharmaceuticalsis

₹ 1013cr

and

Profit

is:

₹ 257cr

GlaxosmithklinePharmaceuticalsProfitisupby:

25.37

%andIncomeisUpby:

19.46

%
TheincomeofGlaxosmithklinePharmaceuticalsis

₹ 848cr

and

Profit

is:

₹ 205cr

GlaxosmithklinePharmaceuticalsProfitisdownby:

21.76

%andIncomeisDownby:

16.45

%
TheincomeofGlaxosmithklinePharmaceuticalsis

₹ 1015cr

and

Profit

is:

₹ 262cr

GlaxosmithklinePharmaceuticalsProfitisupby:

14.41

%andIncomeisUpby:

3.15

%
By using this site you agree to the use of cookies to deliver a better site experience.